Hydrogen Therapy Shows Promise for Parkinson's Disease Treatment
- Authors
- Fengjiao Wang, Guangjie Zhang, Qingfeng Zhai
- Journal
- Frontiers in Neuroscience
- Year
- 2025
- DOI
- 10.3389/fnins.2025.1576773
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Parkinson's Disease
- Body System
- Nervous System
TL;DR
Scientists think a gas called molecular hydrogen might help treat Parkinson's disease by fighting inflammation and damage in the brain, but so far the real-world tests on patients have given mixed results, so they need to do bigger, better studies to figure out if it actually works.
Key Finding
Preclinical studies suggest molecular hydrogen has neuroprotective properties through antioxidant and anti-inflammatory mechanisms, but clinical trials in humans have yielded mixed outcomes, indicating more research is needed to establish real-world effectiveness.
Summary
This review examined how molecular hydrogen might help treat Parkinson's disease, a brain disorder involving protein clumps, cell damage from oxidative stress (harmful chemical reactions), and brain inflammation. Laboratory studies suggest hydrogen could protect brain cells by reducing oxidative stress and inflammation, but clinical trials in humans have produced mixed results—some showing benefit and others showing little to no effect. The authors conclude that while hydrogen shows promise, larger and better-designed human studies are needed to determine if it actually works.
Practical Takeaway
While laboratory evidence suggests hydrogen may have protective effects on brain cells in Parkinson's disease, human clinical trials have not yet confirmed these benefits. This is a review article summarizing existing research rather than a new study, and the authors emphasize that large-scale human trials are still needed before hydrogen can be recommended as a treatment. Anyone considering hydrogen water for Parkinson's should consult their neurologist, as evidence in humans remains inconclusive.
Abstract
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by a pathology that includes the aggregation of alpha-synuclein (α-syn), oxidative stress, and neuroinflammation. While existing treatments can alleviate motor symptoms, they have limited efficacy in slowing disease progression and improving non-motor symptoms. In recent years, molecular hydrogen has been recognized for its potential neuroprotective effects, attributed to its selective antioxidant and anti-inflammatory properties. While preclinical studies demonstrate promising results, clinical trials conducted thus far have yielded mixed outcomes, with some trials reporting limited or no therapeutic benefit. This review systematically analyzes the mechanisms of action of molecular hydrogen in PD and related neurodegenerative disorders, emphasizing its antioxidant, anti-inflammatory, and anti-apoptotic properties. By evaluating evidence from both preclinical and clinical studies, this paper explores the potential of molecular hydrogen to attenuate oxidative stress, modulate inflammatory responses, and inhibit apoptosis in neuronal cells, while also identifying key gaps in current research. As a novel neuroprotective agent, molecular hydrogen holds potential in PD and other neurodegenerative diseases, but further well-designed clinical trials are needed to validate its efficacy. Future studies should focus on elucidating the mechanisms through which hydrogen exerts its neuroprotective effects, particularly concerning α-syn aggregation and its clearance pathways, as well as Nrf2-mediated immunomodulation. Furthermore, large-scale, multicenter clinical trials are necessary to establish efficacy benchmarks and personalized delivery protocols.